AstraZeneca, the stock had a really turbulent time behind them when the company’s China manager was accused of a crime.Perhaps today we will get more and better information that tells us how things are actually going.

AstraZeneca has not been a bad stock to own historically. If you invested in 2007, you would have received just over 13% annually. Sure, that’s not a mega figure, but still quite a lot better than what the Stockholm Stock Exchange’s broad index has done. That said, it would of course have been better to put the money in investment companies like Investor.

In short, it has been a stable piece to own and the last 10 years have been no exception.

At the end of last year, I highlighted Astra Zeneca, stating that their current P/E of 16.4 was much lower than their 5-year average of just over 20. Since then, the share has risen from SEK 1,386/share to SEK 1,524/share.

I thought the report generally looked good, with many key figures being higher than analysts’ predictions.

The total dividend (including the dividend already paid last year) will be $3.1 /share for the 2024 fiscal year. This is an increase from the 2.9 SEK that the company presented a year ago.

This also means that AstraZeneca has 25 years behind it with a positive dividend trend, i.e. where the dividend has not necessarily been increased every year but where it has at least not been lowered.